Emisphere Technologies News

Emisphere Technologies, Inc. today announced the publication of a study assessing the oral delivery of GLP-1 and PYY3-36 using Emisphere's proprietary delivery technology.

Pharmaceuticals Emisphere Technologies is a biopharmaceutical company focused on the development of a family of oral heparin products; the application of proprietary synthetic chemical compounds to serve as ...

GuruFocus Home >> News Home >> Carl Icahn Buys Yahoo! Inc., Motorola Inc., Emisphere Technologies Inc., Sells BEA Systems Inc., GUARANTY FIN GROUP, Perry Ellis International Inc.

Billionaire and activist investor Carl Icahn is a big fan of the biotech sector of late.

Second-quarter losses at Emisphere Technologies Inc. narrowed as the company's 2007 decision to move management from Eastview to New Jersey and to cut staff helped reduce expenses.

Main Category: Bones / Orthopaedics Also Included In: Pharma Industry / Biotech Industry Emisphere Technologies, Inc.

Emisphere Technologies Inc. said yesterday that study results show an oral form of vitamin B-12 that the company is developing reduced the amount of time it took for the body to absorb the nutrient, while ...

Emisphere Technologies Inc. said yesterday that study results show an oral form of vitamin B-12 that the company is developing reduced the amount of time it took for the body to absorb the nutrient, while ...

Emisphere Technologies Inc. said yesterday that study results show an oral form of vitamin B-12 that the company is developing reduced the amount of time it took for the body to absorb the nutrient, while ...

Emisphere Technologies Inc. said yesterday that study results show an oral form of vitamin B-12 that the company is developing reduced the amount of time it took for the body to absorb the nutrient, while ...

Main Category: Diabetes Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 09 Jul 2008 - 1:00 PDT Emisphere Technologies, Inc.

Main Category: Endocrinology Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 01 Jul 2008 - 1:00 PDT Emisphere Technologies, Inc.

Following Thursday and Friday's precipitous selloff in the equity market - and the last month's for that matter - I once again found inspiration to look elsewhere for investment opportunities.

Millions of patients receive injections to treat B12 deficiency, but a new oral option may soon be possible, U.S. researchers said.

Capsules could some day replace intramuscular injections for people with vitamin B12 deficiency, a U.S. company says.

Noven Pharmaceuticals said Monday it has appointed Steven M. Dinh to the newly created position of vice president and chief scientific officer.

Main Category: Bones / Orthopaedics Also Included In: Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 03 Jun 2008 - 2:00 PDT Genta Incorporated announced the release of final ...

Emisphere Technologies, Inc., a publicly held company, is committed to developing breakthrough therapies for oral drug delivery.

“At that point we will be able to demonstrate that, in fact, our technology can provide benefits to the population at large, for whatever treatment it is we are talking about”

Highlighting the company's expectations for the future as well as its current product pipeline, Michael V. Novinski, President and CEO of Emisphere Technologies, Inc. via Med Ad News

Emisphere Technologies Inc., the biopharmaceutical company with research and development operations in Eastview, lost $3.9 million during the first quarter, matching its loss from the first quarter of last ... via The Journal News